Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Completed · Not applicable

Conditions studied: Breast Cancer

In brief

This trial will evaluate the clinical significance of the PRO Onc assay and will assess the efficacy of HER2-targeted therapy in patients with HER2-negative breast cancer who have been identified as having HER2 overexpression/activation by the PRO Onc Assay.

Key facts

Study ID

NCT01048099

Run by

SCRI Development Innovations, LLC

People needed

283

Starts

2011-01-01

Expected to finish

2014-07-01

Last updated by the study team

2016-01-29

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Part I
• Women with HER2-negative breast cancer, as defined by FISH testing. (FISH testing may have been performed on the primary tumor, or subsequently on a biopsy of a metastatic lesion.)
• Patients should be currently receiving chemotherapy, or scheduled to start chemotherapy (second-line or subsequent), for HER2-negative metastatic breast cancer.
• To begin protocol treatment, patients must have progressed after at least 1 previous chemotherapy regimen for metastatic breast cancer.
• Patients who are ER/PR positive or negative are eligible. ER/PR positive patients should be refractory to hormonal therapy, or not good candidates for hormonal therapy due to clinical features.
• ECOG performance status of 0, 1 or 2.
• Adequate recovery from recent surgery; ≥ 1 week must have elapsed from the time of a minor surgery; ≥ 4 weeks must have elapsed from the time of a major surgery.
• Patients must have measurable disease per RECIST criteria.
• Laboratory values as follows: Absolute neutrophil count (ANC) ≥1500/μL Hemoglobin (Hgb) ≥10 g/dL Platelets ≥100,000/L AST or ALT and alkaline phosphatase (ALP) must be <2.5 x ULN, or <5 x ULN in patients with liver metastases. Total bilirubin <1.5 x the institutional ULN Serum creatinine <1.5 x institutional ULN or calculated creatinine clearance ≥45 mL/min
• Patients from Part 1 who have HER2 overexpression/activation identified by the PRO Onc Assay may enter the treatment portion of Part 2, if they meet all Part 2 eligibility criteria.
• Life expectancy of ≥ 12 weeks.
• Patient must be accessible for treatment and follow-up.
• Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry.
• Part II
• Women with HER2-negative breast cancer, as defined by FISH testing. (FISH testing may have been performed on the primary tumor, or subsequently on a biopsy of a metastatic lesion.)
• Patients should be currently receiving chemotherapy, or scheduled to start chemotherapy, for HER2-negative metastatic breast cancer.
• Patients who are ER/PR positive or negative are eligible. ER/PR positive patients should be refractory to hormonal therapy, or not good candidates for hormonal therapy due to clinical features.
• ECOG performance status of 0, 1 or 2.
• Adequate recovery from recent surgery; ≥ 1 week must have elapsed from the time of a minor surgery; ≥ 4 weeks must have elapsed from the time of a major surgery.
• Patients must have measurable disease per RECIST criteria.
• Laboratory values as follows:
• Absolute neutrophil count (ANC) ≥1500/μL
• Hemoglobin (Hgb) ≥10 g/dL
• Platelets ≥100,000/uL
• AST or ALT and alkaline phosphatase (ALP) must be <2.5 x ULN, or <5 x ULN in patients with liver metastases.

You may not qualify if…

• Part I:
• Patients currently responding to hormonal therapy.
• Previous treatment with any HER2-targeted agent.
• Patients with meningeal metastases.
• Patients who are not considered likely candidates for subsequent therapy after next progression of metastatic breast cancer.
• Women who are pregnant or lactating.
• Patients with New York Heart Association class II or greater congestive heart failure.
• Any of the following ≤6 months prior to starting study treatment:
• myocardial infarction;
• severe unstable angina;
• ongoing cardiac dysrhythmia
• Concurrent severe, intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements.
• Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study.
• Use of any non-approved or investigational agent ≤ 30 days of administration of the first dose of study drug. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.
• Part II
• Patients currently responding to hormonal therapy.
• Previous treatment with any HER2-targeted agent.
• Patients with meningeal metastases.
• Patients with active brain metastases. Patients who have received radiation or surgery for brain metastases are eligible if there is no evidence of central nervous system (CNS) disease progression, and at least 4 weeks have elapsed since treatment. Ideally, patients should not still require use of seizure medication or steroids.
• Patients who are not considered likely candidates for subsequent therapy after next progression of metastatic breast cancer.
• Women who are pregnant or lactating.
• Patients with New York Heart Association class II or greater congestive heart failure.
• Any of the following ≤6 months prior to starting study treatment:
• myocardial infarction;
• severe unstable angina;

Where it is running

• Florida Cancer Specialists — Fort Myers, Florida, United States
• Florida Cancer Specialists — St. Petersburg, Florida, United States
• Oncology Hematology Care, Inc. — Cincinnati, Ohio, United States
• Chattanooga Oncology Hematology Associates — Chattanooga, Tennessee, United States
• Tennessee Oncology, PLLC — Nashville, Tennessee, United States
• Center for Cancer and Blood Disorders — Fort Worth, Texas, United States
• Virginia Cancer Institute — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.